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Summary Characteristics of cells that are associated with the hormonal dependence of tumours are
described, and it is shown that clonogenicity and hormone-induced proliferative response of breast tumours
are as good markers of hormonal dependence as is oestrogen receptor. Thus tumours that formed less than
150 colonies per 500,000 cells seeded and that increased their proliferative activity 1.8-fold or more in
response to hormones were the tumours that were likely to respond to endocrine treatments, whereas all other
tumours were likely to be refractory to endocrine treatments. These two criteria (clonogenicity and
proliferative response to growth hormones) correctly identified the response to subsequent endocrine
treatments in 15 out of 17 patients with oestrogen receptor-unknown tumours. It is proposed that they may
constitute a substitute for the oestrogen receptor status in patients with non-biopsiable tumours, and an
additional discriminant where the oestrogen receptor assay is available.
Thirty per cent of breast tumours are hormone-dependent
and can- be managed effectively with endocrine manipula-
tions (Stoll, 1981), but the degree of hormonal dependence
varies among tumours-and changes within tumours as the
disease evolves. A measurement of hormonal dependence is
therefore necessary for the proper management of patients
with breast carcinoma; a requirement that is the more
pressing since tamoxifen has become the recommended adju-
vant treatment for post-menopausal women with oestrogen
receptor-positive and oestrogen receptor-unknown stage II
disease (Cancer Conference, 1985), and more recently also
for similar patients with stage I disease (DeVita, 1988). The
oestrogen receptor (ER) assay identifies with a high degree
of accuracy patients that will not benefit from endocrine
treatment (Desombre, 1975; Wang et al., 1984). However, its
predictive value when positive is only 50%, i.e. inadequate to
select for the type of curative treatment modality (endocrine
versus cytotoxic). Furthermore, smaller tumours will be
diagnosed as a consequence of screening procedures, and
adequate tissue for the ER-assay may often no longer be
available. Hence, the proportion of 'ER-unknown' tumours
will increase, and the 'efficacy' of endocrine treatments will
accordingly decrease. The need has therefore emerged to
improve our ability to predict response to endocrine treat-
ments with additional or more accurate tests that can also be
obtained with lesser tumour tissue.
We have previously observed that the in vitro responsive-
ness of tumours to growth-stimulatory hormones could
provide an estimate for the in vivo responsiveness of tumours
to growth-inhibitory hormones: a high proliferative response
of tumours to a combination of steroid and peptide hor-
mones provided a measure that supplemented a positive ER
assay by identifying patients that responded to endocrine
treatment among those with ER-positive tumours (Hug et
al., 1983).
The purpose of the present report is to describe criteria
that may substitute for the ER assay in patients with non-
biopsiable tumours, e.g. patients with ER-unknown tumours.
Materials and methods
Patients
The tumours of 122 patients with stage IV breast carcinoma
were assayed. Of these, 15 patients with ER-positive tumours
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and 17 patients with ER-unknown tumours received endo-
crine treatments just after the test. The details for treatments
are listed in Tables I and II. All patients had measurable
tumour lesions. Hormones were the first endocrine treatment
for 18 patents, the second endocrine treatment for four
patients and the third endocrine treatment for 10 patients.
Tumour lesions were measured at monthly intervals. The
longest diameters of tumour lesions and their perpendiculars
were determined. A 50% or greater decrease in the sum of
the products of diameters of all measured4lesions persisting
for at least 1 month was defined as treatment response. All
other changes of tumour measures were defined as treatment
non-response, according to the UICC (Union International
contre le Cancer) criteria. Correlations between hormone-
induced proliferative response and clonogenicity of tumours
(as substitutes for the ER assay) and the clinical response of
these patients were obtained.
Tumours
One hundred and fifteen specimens of metastatic tumour
were obtained from the remaining 90 patients with stage IV
breast carcinoma. Seventy-five specimens were obtained from
solid metastatic lesions, generally skin or subcutaneous
tissues; the remaining specimens were derived from malig-
nant effusions (30) and from tumour-involved bone marrows
(10). Solid tumour samples were collected in the Department
of Surgery of University of Texas M.D. Anderson Cancer
Center; malignant effusions and bone marrows were aspir-
ated in the Department of Medical Oncology. Tissues were
collected in 50ml of culture medium, and 1000 U of
preservative-free heparin was added to all samples.
Oestrogen receptor determination
Tumours were assayed for oestrogen receptors in the Depart-
ment of Laboratory Medicine of the M.D. Anderson Cancer
Center. The dextran-coated charcoal method was used to
measure oestrogen receptors (Clark & Peck, 1975). Tumours
that contained above 3fmol oestrogen receptor-protein per
mg cytosol protein were considered ER-positive.
Clonogenicity of tumours
A colony-forming assay in agar cultures was used
(Hamburger & Salmon, 1977). Solid tissues were sliced into
1 mm3 cubes and single cells were teased into suspension with
18-gauge needles. Effusions were centrifuged at 40 x g for
10min and cells resuspended in 5 ml Ham's F12 medium
(F12, GIBCO, Grand Island, NY). (F12 contains 1.2mgl-1
phenol red.) All cell suspensions were incubated in mixture
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Table I In vitro and in vivo hormonal responsiveness of ER-positive breast tumours
ER (fmolmg-1)
265
272
160
71
70
65
27
31
30
11
4
9
8
7
7
Predictor
Clonogenicitya HPR
0.015
0.020
0.026
<0.001
0.004
0.022
0.038
0.010
0.207
0.021
0.066
0.011
0.031
0.006
0.034
2.6
2.1
2.3
32.0
25.0
3.1
2.2
1.0
1.1
0.6
1.4
1.5
1.9
16.5
2.5
Treatment
Oestradiol/Medroxyprogesterone acetate
Tamoxifen
Tamoxifen
Aminoglutethimide
DES
Tamoxifen
Tamoxifen
Tamoxifen
Tamoxifen
Tamoxifen
Megoestrol
Fluoxymestrone
Megestrol
Aminoglutethimide
Aminoglutethimide
aPercentage of seeded cells that had formed colonies.
c.r., complete remission; p.r., partial remission; s.d., stable disease; p.d., progressive disease.
A cut-off of 0.03% is proposed for clonogenicity and of > 1.8 for hormonal sensitivity (HPR).
Table II In vitro and in vivo hormonal responsiveness of ER-
unknown breast tumours
0.005
0.003
0.016
0.008
0.008
0.003
0.069
0.056
0.055
0.059
0.031
0.014
0.014
0.013
0.002
0.002
<0.001
35.9
9.5
2.0
68.5
28.0
2.6
1.5
1.6
1.2
2.2
1.9
1.3
0.7
2.2
1.4
0.7
818.7
Treatment
Tamoxifen
Aminoglutethimide
Aminoglutethimide
Fluoxymestrone
Tamoxifen
Tamoxifen
DES
Megoestrol
Megoestrol
Tamoxifen
DES
Megoestrol
Tamoxifen
Tamoxifen
Tamoxifen
Tamoxifen
Tamoxifen
aPercentage of seeded cells that had formed colonies.
c.r., complete remission; p.r., partial remission; s.d., stable disease;
p.d., progressive disease.
A cut-off of 0.03% is proposed for clonogenicity and of > 1.8 for
hormonal sensitivity (HPR).
of 1.0% Worthington type III collagenase (Worthington
Biochemical Corporation, Freehold, NJ) and 0.005%
deoxyribonuclease (Sigma Chemical Co., St Louis, MO) in
F12 at 37°C for 20h, under continuous agitation. Elastase,
at a concentration of 0.6%, was also used to disaggregate
solid tumours. Cells were washed in calcium- and
magnesium-free Hank's balanced salt solution (GIBCO,
Grand Island, NY) and resuspended in F12 supplemented
with 10% foetal bovine serum (FBS, KC Biological, Lenexa,
KS). Remaining cell aggregates were removed by passing
suspensions sequentially through 18-, 22- and 25-gauge nee-
dles. Cells were then counted with a haemocytometer and set
into agar cultures.
Underlayers of cultures consisted of I ml volumes of a
mixture of 70% F12, 20% conditioned medium and 10%
horse serum (KC Biological, Lenexa, KS), in 0.5% agar
(Bactoager Difco, American Scientific Products). Upper
layers consisted of 1 ml volumes of a mixture of minimal
essential medium (GIBCO, Grand Island, NY) and 15%
FBS, in 0.3% agar. Conditioned medium was obtained from
the supernatants of three breast tumour cell lines (Hug et al.,
1984). Cells were added to the upper layers. Half the tumour
cells were cultured under regular (control) conditions and
half under hormone-supplemented conditions (see below).
One to three replicate cultures were obtained, depending on
sample size. One regular culture was fixed with glutaralde-
hyde and served as a control for contamination of cultures
with cell aggregates.
In most instances 5 x 105 cells were seeded to upper layers.
However, when tumours were too small for biopsy, cells
were aspirated into 2ml 2X serum-supplemented medium
and admixed with 2ml 0.6% agar. One millilitre aliquots of
the mixture were then layered over hormone-supplemented
and regular (control) underlayers.
Cultures were incubated at 37°C in a humidified atmos-
phere of 5% CO2 and 12% 02 in nitrogen for 14 days. A
tissue culture microscope was used to score cultures for
clonogenic tumour growth. Aggregates of 50 or more cells
(>75,um in diameter) and of uniform morphology were con-
sidered to represent the progeny of clonogenic cells and were
counted as colonies. The glutaraldehyde-fixed plates were
scored similarly and 'clumps' so enumerated were subtracted
from the score of cultured plates to arrive at the final colony
count. Clonogenicity was expressed as the percentage of
seeded cells that had formed colonies.
Hormone-induced proliferative response of clonogenic cells
(HPR)
The proliferative response of clonogenic cells to a combi-
nation of steroid and peptide hormones (17-beta-oestradiol,
epidermal growth factor, insulin and hydrocortisone), in
combination, was used as an estimate of the hormonal
dependence of tumours (Lippman & Bolan, 1975; Holley,
1975; Gross et al., 1984). Nine tumours were also assayed
for the responsiveness to 17-beta-oestradiol alone. Hormones
were added to both culture layers as follows: 17-beta-
oestradiol, 5 x 10- 7M; epidermal growth factor, 50ngml-1;
insulin, 10pgml-1; and hydrocortisone, 2.5 pgml-1. At
these concentrations, hormones had maximally stimulated
the growth of four breast tumour cell lines that were
cultured under identical conditions (Hug et al., 1984).
Oestradiol and hydrocortisone were obtained from Sigma
Chemical Corporation (St Louis, MO) and insulin and
epidermal growth factor from Collaborative Resealrch Inc.
(Waltham, MA). The hormone-induced proliferative response
of clonogenic cells was measured as the ratio of colonies
formed under hormone-supplemented conditions to those
formed under regular (control) culture conditions.
Response
c.r.
c.r.
p.r.
p.r.
p.r.
p.r.
p.r.
p.d.
s.d.
s.d.
s.d.
p.d.
p.d.
p.d.
p.d.
Predictor
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Results
Ninety per cent for tumour samples formed one or more
colonies per 500,000 cells seeded. The median clonogenicity
of the 115 tumours was 0.014%, ranging from 0.002 to
1.08%. Solid tumour lesions were more clonogenic (0.02%
median) than malignant effusions (0.004% median), P=0.01.
Forty-four per cent of tumours were ER-positive, 15% ER-
negative and 41% ER-unknown. The median clonogenicity
was 0.02% for ER-negative tumours and 0.014% for ER-
positive tumours (P=0.025).
17-Beta-oestradiol, hydrocortisone, epidermal growth
factor and insulin increased the proliferative activity of 96%
of all tumours tested. The relative effects of 17-beta-
oestradiol alone and those of the combined hormones are
illustrated in Figure 1. In this group of nine tumours, a
substantial increase in colony-formation occurred with the
exposure to 17-beta-oestradiol in all instances; the remaining
hormones medited a further increase.
We observed an inverse relationship between clonogenicity
of tumours and proliferative response to hormones. As
clonogenicity of tumours increased, the proliferative response
to hormones decreased (difference not significant).
Although ER-positive tumours tended to be more respon-
sive to the combined hormones (Figure 2), the difference in
proliferative response of ER-positive and ER-negative
tumours was not significant. It is of note that all but two of
the oestrogen receptor-negative tumours (15/17) responded
to growth stimulation.
The ER-positive tumours (Figure 2) were further analysed
to quantitate the level of ER activity as a function of
hormone-induced proliferative response, i.e. a comparison of
biochemical (ER) vs biological (HPR) evaluation of hormonal
dependence of tumours. The concentration of oestrogen
receptors did not correlate with the proliferative response of
tumours to hormones.
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Figure 1. Relative contribution of 17-beta-oestradiol to the
growth-stimulatory effects of four growth substances (17-beta-
oestradiol, hydrocortisone, epidermal growth factor and insulin).
Each dot represents the mean clonogenicity (percentage of seeded
cells that had formed colonies) from triplicate cultures of one
tumour: under regulator culture conditions, under 17-beta-
oestradiol supplemented conditions and under conditions supple-
mented with all four hormones.
c- IL
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Figure 2 Hormone-induced proliferative response (HPR) and
oestrogen receptor status of tumours. The mean values of
triplicate cultures have been plotted. While the proliferative
response of ER-positive tumours is greater, the oestrogen recep-
tor measure is an incomplete evaluation of the tumour's hor-
monal dependence.
The relationships of clonogenicity and proliferative re-
sponse to hormones were analysed as a function of the ER-
status of tumours. The findings are illustrated in Figure 3.
The observed differences in intrinsic hormonal dependence of
tumours with different oestrogen-receptor status were best
appreciated in the respective hormone-induced proliferative
response versus clonogenicity curves, fitting the ratios of the
number of colonies formed with hormones versus control
against controls (Figure 3 caption). The regression line for
ER-positive tumours had a steeper slope and a higher x-
intercept than that of ER-negative tumours. The values for
ER-unknown tumours were intermediate. A significant rela-
tionship of clonogenicity and hormone-induced proliferative
response existed only for ER-negative and ER-unknown
tumours. For ER-positive tumours, the relative increment in
colony-formation in the presence of hormones was related
inversely to the clonogenicity and was of independent prog-
nostic significance. This increased proliferative response to
hormones of low-clonogenic tumours could therefore be
used as a criterion to select out the ER-positive proportion
of tumours among ER-unknown tumours. Whatever the
oestrogen-receptor status of the tumours, however, hormones
increased the proliferative activity of the low-clonogenic
tumours to a higher degree than that of the high-clonogenic
tumours.
We defined the assay's worth for estimating the hormonal
dependence of breast tumours by comparing the outcome of
the assay with the clinical response of patients to endocrine
treatments. Thirty-two patients received endocrine treatment
just after the test. In the 15 patients with ER-positive
tumours (listed in Table I), a 1.8-fold or higher increase of
hormone-induced proliferative activity (HPR) identified all424 V. HUG et al.
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Figure 3 Fittings of ratios of number of colonies with hormones
versus number of colonies without hormones against untreated
controls for each class of receptors status. A, ER-positive; *,
ER-negative. Values for ER-unknown tumours were intermediate
and have been omitted for clarity. Unlike the case for ER-
negative and ER-unknown tumours the relationship between
clonogenicity and hormone-induced proliferative response for
ER-positive tumours is not linear, and proliferative response
increases as colony-formation decreases. The slope that fits
hormone-induced proliferative response with controls for the ER-
unknown tumours indicates that these tumours are composed of
20% ER-positive and 80% ER-negative tumours. This estimate
is in accordance with the clinical expectation. ER-positive
r=-0.83+0.12 (s.e.), P=0.164 against slope of -1; ER-
unknown r= -0.56+0.13, P =0.003; ER-negative
r=-0.49 +0.22, P =0.033.
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Figure 4 Hormone-induced proliferative response (HPR) and
clonogenicity (percentage of seeded cells that had formed col-
onies) of tumours in relation to the clinical response to endocrine
treatment. Values from patients with ER-positive tumours are
plotted in a. Values from patients with ER-unknown tumours
are plotted in b. A, tumours of patients who achieved a complete
or partial remission; *, tumours of patients who achieved less
than a partial remission. The shift of distribution of HPR for
responders and non-responders among patients with ER-positive
tumours was significant (P=0.02, two-tailed Wilcoxon rank sum
test). However, HPR alone could not significantly separate
responders from failures in patients with ER-unknown tumours
(P=0.09, two-tailed Wilcoxon rank sum test); nor could clonoge-
nicity alone discriminate these two group (P=0.46). The discri-
minant analysis using both criteria is shown in Table III.
seven patients that subsequently responded to endocrin
treatment and five of eight patients that failed to respon
(Figure 4a). The shift of distribution of HPR for responder
and failures was significnt at the P=0.02 level (two-taile
Wilcoxon rank sum test).
In 17 patients the ER status was not known. The charac
teristics of these patients with non-biopsiable tumours ar
listed in Table II, and their responses to endocrine treal
ments were analysed in terms both of clonogenicity and c
hormone-induced proliferative response (HPR) (Figure 4b).
As can be seen, neither the shift of distribution of clonogeni-
city nor of HPR alone could significantly separate re-
sponders and non-responders to endocrine treatment among
this group of patients with ER-unknown disease. The P
values were 0.46 and 0.09, respectively (two-tailed Wilcoxon
rank sum test). However, since hormone-dependent tumours
were less clonogenic, the separation became more precise if
the criterion for hormonal dependence of a 1.8-fold or
greater increase in hormone-induced proliferative activity
was restricted to tumours that formed less than 150 colonies.
The combined criteria allowed 88% of patients to be cor-
rectly classified. A discriminant analysis for the combined
criteria was performed (Table III) and yielded the following
function: y =-20 +0.43 lnHPR-0.0043 x number of col-
onies (y>0 for responders and y<0 for failures). The same
analysis was also performed for ER-positive and ER-
unknown tumours combined, and the results are shown in
Table III.
No retrospective correlations of in vitro and in vivo
hormonal responsiveness of ER-negative tumours were
obtained, because the predictive value of a negative ER-
assay result is close to 90% and patients with a negative test
rarely receive endocrine treatments. Thus, we are not certain
what the clinical meaning of the hormone-induced prolifera-
tive response of ER-negative tumours means. It is possible
that our measures reflect growth-stimulation mediated by
epidermal growth factor.
Discussion
We have previously reported that the in vitro response of
breast tumours to growth-stimulatory hormones provided an
estimate of the in vivo response to growth-inhibitory hor-
mones. The present paper is concerned with predictors of
response of ER-unknown tumours, e.g. patients with non-
biopsiable tumours. We found that clonogenicity of tumours
was a determinant of hormonal dependence of tumours: low-
clonogenic tumors tended to be hormone-dependent and
high-clonogenic tumours tended to be hormone-independent.
Clonogenicity was, in fact, a more powerful predictor of
hormonal dependence of tumours than was the oestrogen
receptor status of tumours. As illustrated by the hormone-
induced proliferative response versus clonogenicity curves, the
s differences in slopes of ER-positive and ER-negative
tumours reflected a higher degree of endocrine dependence
of ER-positive tumours. However, the magnitude of the
effect was relatively small, and the absence of this infor-
mation did not jeopardise the discriminatory power of
clonogenicity, as can be seen from our analysis of ER-
unknown tumours.
Conversely the proliferative response to hormones of low-
clonogenic tumours was significantly higher for ER-positive
tumours than for all others and there was no inverse
Table III Discriminant analyses of HPR and clonogenicity in rela-
tion to clinical response
Clinical
response
ie
Id
rs
,d
c-
re
t-
:f
No. of
cases
Predicted response
Failures Responders
For patients with ER-unknown tumours:
Failures 12 11 (92%) 1 (8%)
Responders 5 1 (20%) 4 (80%)
Function: y -0.20+0.43 x In HPR-0.0043 x number of colonies
For all patients:
Failures 20 18 (90%) 2 (10%)
Responders 12 6 (50%) 6 (50%)
Function: y -0.44+0.56 x ln HPR-0.0020 x number of colonies
y<0=failure; y>0 = response, number of colonies is per 500,000
cells seeded.
.m
IL
'L ML
0
1-
m
0
arelationship of growth increment upon stimulation and
colony formation, indicating that hormone-induced prolifera-
tive response is an independent variable of the hormonal
dependence of tumours.
Our findings thus indicate that tumours characterised by
low clonogenicity and a high proliferative response to hor-
mones have a high likelihood of responding to endocrine
treatments, whereas all other tumours (high-clonogenic or
low-clonogenic hormone-non-responsive) do not. Using the
criteria for hormone dependence either of formation of less
than 150 colonies and a 1.8-fold or higher increase in
hormone-induced proliferative activity, or of the discriminant
function that best separated our data, we could correctly
identify the clinical response to endocrine treatment in 15 of
17 patients with ER-unknown tumours. Because this simple
and inexpensive biological test requires only 106 cells, a
number of cells that can be obtained by aspiration, it could
potentially substitute for the ER-assay in patients with non-
biopsiable tumours.
One interpretation of these observations is that high-
clonogenic tumours have acquired growth autonomy, where-
as low-clonogenic tumours remain under the control of
external growth factors, and that the development of hor-
monal independence might be an evolutionary phenomenon.
Correlations between clonogenicity of tumours and impaired
survival of patients are in fact generally positive, and a
shared ability of cells to survive the toxicity of concentrated
agar and to kill the host may exist. Hence, it is possible that
clonogenicity, like oestrogen receptors, is more closely
related to differentiation than to oestrogen-dependence of
tumours (clonogenicity being a measure of dedifferentiation
and oestrogen receptors a measure of differentiation), and
HORMONE RESPONSE PREDICTORS 425
that the goodness of the test will ultimately depend on the
relative completeness of the in vitro exposure to hormones
and factors that regulate growth and differentiation of the
mammary gland and/or of breast tumours in vivo.
In summary, our findings indicate that clonogenicity of
tumours and the proliferative response of clonogenic cells to
hormones together may provide measures of the hormonal
dependence of breast tumours. Hormone-induced prolifer-
ative response of clonogenic cells could identify the re-
sponders among patients with ER-positive tumours; and
proliferative response in conjunction with clonogenicity
could substitute for the ER-assay in patients with non-
biopsiable tumours. Certainly, this hypothesis is data-
generated and should be verified in an independent sample
of ER-unknown tumours.
The need for a test that supplements the oestrogen
receptor assay is high. The efficacy of antitumour treatment
depends on its inherent potential as well as on its proper
application. Proper application is most important if treat-
ment is used for cure and its effect cannot be measured.
Proper allocation of available treatments could increase the
cure rate of patients with early breast carcinoma by 35%, if
the hormonal dependence of all (and not just half) the
tumours could be assessed and if the hormonal dependence
could be estimated with a test that provides a predictive
value positive of 90% (and not just 50%). Thus, emphasis
on developing more powerful predictive tests seems justified
and necessary for the effective modulation of the disease
course.
We would like to thank Ozella E. Walton for assistance in pre-
paration of the manuscript and Walter Pagel for editing.
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